CENTER FOR SINGLE PHOTON-EMITTING CANCER IMAGING AGENTS

单光子发射癌症成像剂中心

• 批准号: 6782744
• 负责人: Wynn A Volkert
• 金额: $ 200万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6782744
• 关键词: clinical research; neoplasm /cancer; peptides; phage display; radionuclide imaging /scanning

(Revised Abstract) DESCRIPTION (provided by applicant): The overall goal of the Center for Single Photon-Emitting Cancer Imaging Agents at the University of Missouri-Columbia (MU) is to foster interdisciplinary research to enable development of novel radiolabeled molecular imaging agents capable of selective in vivo uptake and retention in cancer cells. The Research Components and Development Projects supported by this grant are primarily focused on identification of single-photon emitting, site-directed in vivo targeting biomolecular-conjugates directed to cell surface receptors, antigens and angiogenesis markers with high specificity. Many of the bioconjugates developed in this ICMIC are designed to allow corresponding analogues labeled with particle-emitting radionuclides to be produced for potential radiotherapeutic applications. Molecular biology and biochemical techniques form the primary approach for the design and generation of new cancer targeting vectors, including in vivo phage display, combinatorial chemistry/biochemistry, and SPPS. The In vivo Cellular and Molecular Imaging Center (ICMIC) grant will provide essential support to maintain current and catalyze expansion of research teams which are composed of scientists that combine expertise in molecular biology, chemistry, radiopharmaceutical chemistry, comparative oncology, pharmacology, tumor biology and nuclear imaging. The major thrust of the research that will be conducted in the ICMIC will involve the development of 99mTc-, 111In-and 123I-labeled SPECT imaging agents. The radiolabeled bioconjugates to be designed and studied will selectively bind with high affinity to a variety of cancers, including breast, pancreatic, melanoma, lymphoma, prostate and lung cancers. Specialized Resources (Cores) supported by the ICMIC provide critical infrastructure and expertise to support cross-disciplinary research activities conducted in the Research Components and the Development Projects. The ICMIC will facilitate expansion and enhance the scope and quality of radiopharmaceutical sciences research related to development of novel, highly specific cancer targeting imaging agents. The scientific advances made in this program will foster new interdisciplinary research programs with other investigators at both this and extramural institutions, including other ICMICs and Pre-ICMICs.

（修订的摘要）描述（申请人提供）：密苏里州哥伦比亚大学（MU）的单个光子发射癌症成像剂中心的总体目标是促进跨学科研究以促进新型放射性标记分子成像的发展在癌细胞中选择性体内摄取和保留率。 该赠款支持的研究组件和开发项目主要集中于鉴定单光子发射的鉴定，该批准是针对针对细胞表面受体，抗原和血管生成标志物的生物分子偶联物的体内定向的，具有高特异性。在此ICMIC中开发的许多生物缀合物旨在允许与颗粒发射放射性核素标记的相应类似物用于潜在的放射性疗法应用。分子生物学和生化技术构成了新的癌症靶向载体的主要方法，包括体内噬菌体显示，组合化学/生物化学和SPPS。体内细胞和分子成像中心（ICMIC）赠款将提供基本的支持，以维持当前和催化研究团队的扩展，这些研究团队由科学家组成，这些科学家在分子生物学，化学，放射性药物化学，比较肿瘤学，药理学，药物学，肿瘤生物学和肿瘤生物学和肿瘤生物学和肿瘤生物学和肿瘤学，肿瘤学，肿瘤学，肿瘤学，肿瘤学，肿瘤学，肿瘤学，肿瘤生物学和药理学，肿瘤生物学和药理学，肿瘤生物学和药理学，和核成像。 ICMIC中将进行的研究的主要作用将涉及开发99mtc-，111in和123i标记的Spect Imaging剂。要设计和研究的放射标记的生物缀合物将与各种癌症有选择地结合，包括乳腺癌，胰腺，黑色素瘤，淋巴瘤，前列腺癌和肺癌。 ICMIC支持的专业资源（核心）提供了关键的基础设施和专业知识，以支持研究组件和开发项目中进行的跨学科研究活动。 ICMIC将促进与新型癌症靶向成像剂的开发有关的放射药科学研究的范围和质量。该计划中的科学进步将与其他研究人员和壁外机构（包括其他ICMICS和ICMICS）一起培养新的跨学科研究计划。